A novel series of quinolizidine salicylamides was synthesized as specific inhibitors of the H1 subtype of influenza A viruses. These inhibitors inhibit the pH-induced fusion process, thereby blocking viral entry into host cells. Compound 16 was the most active inhibitor in this series with an EC50 of 0.25 mu g/mL in plaque reduction assay. The synthesis and the SAR of these compounds are discussed. (C) 1999 Elsevier Science Ltd. All rights reserved.
作者:Kuo-Long Yu、Edward Ruediger、Guangxiang Luo、Christopher Cianci、Stephanie Danetz、Laurence Tiley、Ashok K. Trehan、Ivo Monkovic、Bradley Pearce、Alain Martel、Mark Krystal、Nicholas A. Meanwell
DOI:10.1016/s0960-894x(99)00361-3
日期:1999.8
A novel series of quinolizidine salicylamides was synthesized as specific inhibitors of the H1 subtype of influenza A viruses. These inhibitors inhibit the pH-induced fusion process, thereby blocking viral entry into host cells. Compound 16 was the most active inhibitor in this series with an EC50 of 0.25 mu g/mL in plaque reduction assay. The synthesis and the SAR of these compounds are discussed. (C) 1999 Elsevier Science Ltd. All rights reserved.
Substituted benzamides with conformationally restricted side chains. 1. Quinolizidine derivatives as selective gastric prokinetic agents
作者:Michael S. Hadley、Frank D. King、Brian McRitchie、David H. Turner、Eric A. Watts
DOI:10.1021/jm00150a015
日期:1985.12
ring retain gastric activity. Of these 2-substituted compounds, the 2 alpha, 9a alpha isomer has potentselectivegastricprokinetic activity with only weak dopamine antagonist properties. Spectroscopic data show that the quinolizidine ring preferentially adopts a trans chair-chair conformation with an axial benzamide moiety. However, energy calculations indicate that, at nondopaminergic receptors controlling